Charles River Laboratories | CRL - Debt

Stock Price
181.98
Daily Change
-19.64 -9.74%
Monthly
-15.79%
Yearly
9.45%
Q1 Forecast
204.00

Charles River Laboratories reported $2.79B in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Agilent USD 3.41B 640M Jun/2025
Align Technology USD 121.27M 1.75M Sep/2025
Bio-Rad Laboratories USD 1.41B 204.6M Jun/2025
Bruker USD 2.44B 321.5M Jun/2025
Cardinal Health USD 9.03B 505M Sep/2025
Charles River Laboratories USD 2.79B 74.83M Jun/2025
Cigna USD 30.77B 320M Jun/2025
CVS Health USD 65.84B 654M Sep/2025
Danaher USD 18.42B 1.56B Dec/2025
Dentsply International USD 2.49B 159M Jun/2025
Elevance Health USD 32.05B 56M Dec/2025
Galapagos EUR 10.86M 864K Mar/2025
Hologic USD 2.63B 104.3M Sep/2025
Humana USD 12.61B 21M Sep/2025
Illumina USD 2.58B 22M Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
IQVIA Holdings USD 15.72B 767M Dec/2025
Laboratory Of America USD 6.55B 26.4M Jun/2025
Lonza CHF 4.71B 915M Dec/2024
McKesson USD 9.79B 141M Sep/2025
Merck EUR 9.4B 704M Jun/2025
Mettler Toledo International USD 2.21B 25.94M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Quest Diagnostics USD 6.38B 525M Jun/2025
Revvity USD 3.37B 5.86M Sep/2025
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
UnitedHealth USD 78.39B 1.75B Dec/2025
Waters USD 1.54B 36.51M Jun/2025
West Pharmaceutical Services USD 202.7M 100K Sep/2025